Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30750234 | 0.92 | TAAR1 (0.57) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL5240585 | 0.89 | TAAR1 (0.68) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL19524669 | 0.86 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL30688447 | 0.86 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL705920 | 0.86 | TAAR1 (0.65) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL4402199 | 0.86 | TDP1 (0.46) | TAAR1MAOBTDP1CYP1A2CYP2D6 | |
| SCHEMBL4399626 | 0.84 | TAAR1 (0.74) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL5139428 | 0.83 | TAAR1 (0.61) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL13569139 | 0.83 | TAAR1 (0.61) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL4628953 | 0.82 | TAAR1 (0.47) | TAAR1IDO1AGXTMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3192794-A1 | SUSTAINED HIV PROTEASE INHIBITOR | Shionogi & Co., Ltd. (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-1863794-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | Targegen, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006101977-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| US-3939084-A | Functional fluid compositions containing substituted pyrimidines | MONSANTO COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | TAAR1 3920/4885IDO1 487/4885AGXT 1907/4885 |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | TAAR1 2550/4885IDO1 1084/4885AGXT 2818/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TAAR1 2092/4885IDO1 2380/4885AGXT 1774/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | TAAR1 197/4885IDO1 5/4885AGXT 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.